Biochip Technology Improves Sickle Cell Disease Outcomes
By LabMedica International staff writers Posted on 28 Dec 2014 |
Image: Peripheral blood smear of a patient with hemoglobin SS disease. Arrows indicate classic sickle cells (Photo courtesy of the University of North Carolina).
Although it is well-known that red cell interactions are important in sickle cell disease, the technology to date has not allowed physician-scientists to evaluate these properties on a large scale basis.
An innovative biochip, which evaluates the biophysical properties of red blood cells in sickle cell patients, has the potential to become a standard test for monitoring the disease because of its widespread applicability and its use of only small volumes of blood.
Scientists at the Case Western Reserve University School of Medicine (Cleveland, OH, USA) designed a biochip to examine the biophysical properties of red blood cells, which in sickle cell patients crystalize to cause stiffness and cell deformity. The team used the technology to examine surplus blood samples and found that sickle cell patients had alterations in the biophysical properties of their red blood cells compared to individuals without the disease.
Sickle cell disease is an inherited blood disorder that affects about three million people worldwide with an estimated 100,000 in the USA and causes pain crises, widespread organ damage and early mortality. The team have just opened a new clinical trial for 100 adult and pediatric patients. The follow-up study is aimed at correlating the cellular adhesion measurements with patient outcomes such as pain crises.
Jane Little, MD, director of the Adult Sickle Cell Anemia Center, University Hospital Case Medical Center (Cleveland, OH, USA) and associate professor at the School of Medicine, said, “This new technology gives us a better understanding of the disease and provides us with an important new tool to enhance the monitoring and medical management of patients with sickle cell. If we can begin to identify and predict when patients will have flare-ups in their disease, we can avoid complications by more effectively treating them before their symptoms worsen.” The study was presented at the 56th Annual Meeting of the American Society of Hematology, held December 6–9, 2014, in San Francisco (CA, USA).
Related Links:
Case Western Reserve University School of Medicine
University Hospital Case Medical Center
An innovative biochip, which evaluates the biophysical properties of red blood cells in sickle cell patients, has the potential to become a standard test for monitoring the disease because of its widespread applicability and its use of only small volumes of blood.
Scientists at the Case Western Reserve University School of Medicine (Cleveland, OH, USA) designed a biochip to examine the biophysical properties of red blood cells, which in sickle cell patients crystalize to cause stiffness and cell deformity. The team used the technology to examine surplus blood samples and found that sickle cell patients had alterations in the biophysical properties of their red blood cells compared to individuals without the disease.
Sickle cell disease is an inherited blood disorder that affects about three million people worldwide with an estimated 100,000 in the USA and causes pain crises, widespread organ damage and early mortality. The team have just opened a new clinical trial for 100 adult and pediatric patients. The follow-up study is aimed at correlating the cellular adhesion measurements with patient outcomes such as pain crises.
Jane Little, MD, director of the Adult Sickle Cell Anemia Center, University Hospital Case Medical Center (Cleveland, OH, USA) and associate professor at the School of Medicine, said, “This new technology gives us a better understanding of the disease and provides us with an important new tool to enhance the monitoring and medical management of patients with sickle cell. If we can begin to identify and predict when patients will have flare-ups in their disease, we can avoid complications by more effectively treating them before their symptoms worsen.” The study was presented at the 56th Annual Meeting of the American Society of Hematology, held December 6–9, 2014, in San Francisco (CA, USA).
Related Links:
Case Western Reserve University School of Medicine
University Hospital Case Medical Center
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data